Prise en charge et accompagnement d'un malade cancéreux à tous les stades de la maladie : Traitements symptomatiques : Modalités de surveillance problèmes psychologiques, éthiques et sociaux = Care of the patients with cancer at all the stages of the disease : symptomatic treatments, methods of monitoring psychological, ethical and social problemsDURANDO, Xavier; CURE, Hervé.La Revue du praticien (Paris). 2004, Vol 54, Num 17, pp 1949-1955, issn 0035-2640, 7 p.Article

Assessment of circadian rhythms by actimetry in healthy subjects and patients with advanced colorectal cancerCHEVALIER, Virginie; MORMONT, Marie-Christine; CURE, Hervé et al.Oncology reports. 2003, Vol 10, Num 3, pp 733-737, issn 1021-335X, 5 p.Article

La cancérologie intégrative ou l'utilisation des thérapies complémentaires. À propos d'un modèle américain = External review of integrative oncology or complementary therapies use. Based on US academic cancer centerBRAMI, Cloé; BOUCHE, Olivier; KARP, Jean-Claude et al.Bulletin du cancer. 2014, Vol 101, Num 6, pp 531-532, issn 0007-4551, 2 p.Article

Cancer de l'ovaire. Compte rendu des 9èmes Biennales Monégasques de CancérologieCURE, Hervé; GUASTALLA, Jean-Paul; PAUTIER, Patricia et al.Oncologie (Paris). 2010, Vol 12, Num 4, issn 1292-3818, 14 p., SUP1Serial Issue

Indications, contre-indications, résultats attendus et choix de la chimiothérapie néoadjuvante du cancer du sein opérable : Traitements néoadjuvants = Indications, contra-indications, expected results and choice of neoadjuvant chemotherapy for operable breast cancerMOURET-REYNIER, Marie-Ange; ABRIAL, Catherine; LEHEURTEUR, Marianne et al.Bulletin du cancer. 2006, Vol 93, Num 11, pp 1121-1129, issn 0007-4551, 9 p.Article

Prognostic value of residual node involvement in operable breast cancer after induction chemotherapyCURE, Hervé; AMAT, Sophie; PENAULT-LLORCA, Frédérique et al.Breast cancer research and treatment. 2002, Vol 76, Num 1, pp 37-45, issn 0167-6806, 9 p.Article

Perspectives en cancérologie pour les médecins généralistes: enquête interrégionale 2010 = Prospects in oncology for general practitioners inter-regional 2010 surveyNGUYEN, Tan-Dat; VINCENT, Philippe; LAMBERTH, Fanny et al.Bulletin du cancer. 2011, Vol 98, Num 10, pp 1143-1152, issn 0007-4551, 10 p.Article

Positron Emission Tomography in oncology: Present and future of PET and PET/CT : Imaging and Cancer: Part IIIPAPATHANASSIOU, Dimitri; BRUNA-MURAILLE, Claire; LIEHN, Jean-Claude et al.Critical reviews in oncology/hematology. 2009, Vol 72, Num 3, pp 239-254, issn 1040-8428, 16 p.Article

A phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer : results of the ERASME 3 studyCASSIER, Philippe A; CHABAUD, Sylvie; AGOSTINI, Cecile et al.Breast cancer research and treatment. 2008, Vol 109, Num 2, pp 343-350, issn 0167-6806, 8 p.Article

Circulating chromogranin a and hormone refractory prostate cancer chemotherapyCABRESPINE, Aurélie; GUY, Laurent; GACHON, Francoise et al.The Journal of urology. 2006, Vol 175, Num 4, pp 1347-1352, issn 0022-5347, 6 p.Conference Paper

La cancérologie intégrative: Le modèle du Memorial Sloan Kettering Cancer Center de New YorkBRAMI, Cloé; JOVENIN, Nicolas; BOUCHE, Olivier et al.Onko +. 2013, Vol 5, Num 38, pp 61-70, issn 2101-9495, 10 p.Article

Randomized Phase III Study of Erlotinib Versus Observation in Patients With No Evidence of Disease Progression After First-Line Platin-Based Chemotherapy for Ovarian Carcinoma: A European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup StudyVERGOTE, Ignace B; JIMENO, Antonio; LESOIN, Anne et al.Journal of clinical oncology. 2014, Vol 32, Num 4, pp 320-326, issn 0732-183X, 7 p.Article

Failure of high-dose cyclophosphamide and etoposide combined with double-dose cisplatin and bone marrow support in patients with high-volume metastatic nonseminomatous germ-cell tumours : Mature results of a randomised trial. CommentaryDROZ, Jean-Pierre; KRAMAR, Andrew; CULINE, Stephane et al.European urology. 2007, Vol 51, Num 3, pp 739-748, issn 0302-2838, 10 p.Article

Randomized phase II study comparing paclitaxel and carboplatin versus mitoxantrone in patients with hormone-pefractory prostate cancerCABRESPINE, Aurélie; GUY, Laurent; KHENIFAR, Elhani et al.Urology (Ridgewood, NJ). 2006, Vol 67, Num 2, pp 354-359, issn 0090-4295, 6 p.Article

Place de l'anatomopathologie dans l'évaluation de la réponse à la chimiothérapie néoadjuvante : Marqueurs pronostiques et prédictifs. L'exemple du cancer du sein : Chimiothérapie néoadjuvante = Place of anatomopathology in evaluation of response to neoadjuvant chemotherapy. Prognostic and predictive markers : example of breast cancerABRIAL, Catherine; BOUCHET-MISHELLANY, Florence; RAOELFILS, Inès et al.Bulletin du cancer. 2006, Vol 93, Num 7, pp 663-668, issn 0007-4551, 6 p.Article

Place de la chimiothérapie intensive dans le traitement du cancer épithélial évolué de l'ovaire = High-dose chemotherapy in advanced epithelial ovarian cancerCURE, Hervé; BAY, Jacques-Olivier; PLAGNE, Robert et al.Bulletin du cancer. 2001, Vol 88, Num 9, pp 842-851, issn 0007-4551Article

Traitement systémique de la rechute: une nouvelle donne ?ALEXANDRE, Jérôme; CURE, Hervé; HARDY-BESSARD, Anne-Claire et al.Oncologie (Paris). 2011, Vol 13, Num 4, issn 1292-3818, S41-S46, SUP2Article

Mésothéliome péritonéal : longue survie sous chimiothérapie intrapéritonéale, lanréotide et mucolytiques = Peritoneal mesothelioma : Long survival with intraperitoneal chemotherapy, lanreotide and mucolyticsMONTMAYEUR, Gaëlle; THIVAT, Emilie; GIMBERGUES, Pierre et al.Gastroentérologie clinique et biologique. 2008, Vol 32, Num 10, pp 874-875, issn 0399-8320, 2 p.Article

High prognostic significance of residual disease after neoadjuvant chemotherapy : a retrospective study in 710 patients with operable breast cancerAMAT, Sophie; ABRIAL, Catherine; CURE, Hervé et al.Breast cancer research and treatment. 2005, Vol 94, Num 3, pp 255-263, issn 0167-6806, 9 p.Article

A multicenter phase II study of cisplatin and docetaxel (Taxotere) in the first-line treatment of advanced ovarian cancer: a GINECO studyDIERAS, Véronique; GUASTALLA, Jean Paul; PUJADE-LAURAINE, Eric et al.Cancer chemotherapy and pharmacology. 2004, Vol 53, Num 6, pp 489-495, issn 0344-5704, 7 p.Article

A Phase 2 Trial of Whole-brain Radiotherapy Combined With Intravenous Chemotherapy in Patients With Brain Metastases From Breast CancerCASSIER, Philippe A; RAY-COQUARD, Isabelle; BLAY, Jean-Yves et al.Cancer. 2008, Vol 113, Num 9, pp 2532-2538, issn 0008-543X, 7 p.Article

High-dose chemotherapy with haematopoietic stem cell transplantation for metastatic breast cancer patients: final results of the French multicentric randomised CMA/PEGASE 04 protocolLOTZ, Jean-Pierre; CURE, Hervé; LAADEM, Abderrahmane et al.European journal of cancer (1990). 2005, Vol 41, Num 1, pp 9-11, issn 0959-8049, 13 p.Article

Phase II clinical trial of ixabepilone (BMS-247550), an epothilone b analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapyROCHE, Henri; YELLE, Louise; LEBWOHL, David et al.Journal of clinical oncology. 2007, Vol 25, Num 23, pp 3415-3420, issn 0732-183X, 6 p.Article

Scarff-Bloom-Richardson (SBR) grading: a pleiotropic marker of chemosensitivity in invasive ductal breast carcinomas treated by neoadjuvant chemotherapyAMAT, Sophie; PENAULT-LLORCA, Frederique; CURE, Herve et al.International journal of oncology. 2002, Vol 20, Num 4, pp 791-796, issn 1019-6439Article

Localization of human BRCA1 and BRCA2 in non-inherited colorectal carcinomas and matched normal mucosasBERNARD-GALLON, Dominique J; DE LATOUR, Monique Peffault; HIZEL, Candan et al.Anticancer research. 2001, Vol 21, Num 3B, pp 2011-2020, issn 0250-7005Article